NCT03326180 (SPAARK) is a Phase 3 clinical trial of Liposomal bupivacaine in Knee Osteoarthritis, sponsored by University of Leeds.

Who is sponsoring NCT03326180?

NCT03326180 is sponsored by University of Leeds.

What drugs are being tested in NCT03326180?

Interventions in NCT03326180: Liposomal bupivacaine, Bupivacaine hydrochloride.

What condition does NCT03326180 study?

NCT03326180 studies Knee Osteoarthritis.

Is NCT03326180 still recruiting?

NCT03326180 is currently completed. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT03326180: SPAARK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Peri-Articular Anaesthetic for Replacement of the Knee

Completed Phase 3 Last updated 4 November 2022

What this trial tests

Phase 3 trial testing Liposomal bupivacaine in Knee Osteoarthritis in 533 participants. Completed in 21 April 2021.

Timeline

29 March 2018

Primary endpoint
28 February 2021

21 April 2021

Quick facts

Lead sponsor	University of Leeds
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	533
Start date	29 March 2018
Primary completion	28 February 2021
Estimated completion	21 April 2021
Sites	11 locations across United Kingdom

Drugs / interventions tested

Liposomal bupivacaine
Bupivacaine hydrochloride (Bupivacaine Hydrochloride) — full drug profile →

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

University of Leeds

Who can join

18 and older, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The clinical and cost effectiveness of peri-articular liposomal bupivacaine plus bupivacaine hydrochloride compared with bupivacaine hydrochloride alone for post-operative recovery after knee replacement surgery: A multi-centre, patient-blinded, randomised controlled trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Liposomal bupivacaine

Trials testing the same drug.

NCT06704698 — Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery · NA · recruiting
NCT06575699 — Rectus Sheath Block for Analgesia After Gynecological Laparotomy · Phase 4 · completed
NCT06575010 — Exparel v Dexamethasone in RCR · Phase 4 · enrolling by invitation
NCT06569953 — Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chron · Phase 4 · recruiting
NCT06405724 — Comparison of the Ultrasound-guided Paravertebral Nerve Block With Liposomal Bupivacaine Versus Ropivacaine for Post-Sur · Phase 3 · not yet recruiting

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other University of Leeds trials

Trials by the same sponsor.

NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins · NA · not yet recruiting
NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain · NA · not yet recruiting
NCT07247812 — tSCS in Children and Young People With HCP · NA · not yet recruiting
NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
NCT06240403 — Digoxin and Senolysis in Heart Failure and Diabetes Mellitus · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03326180 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leeds
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03326180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing